Adrian Stroilescu

Adrian Stroilescu, MD is Board Member at Walmark and serial entrepreneur, being involved in five exits until now. He has been working and investing in the healthcare business for 20 years. This includes high level positions in sales, marketing and business development in companies involved in distribution and production, as well as private medical service providers (including hospitals), stem cell banks and CROs. The positions have included Chairman & CEO at Labormed (60mio EUR turnover), Business Development Director for Europe at Ranbaxy (whose European division had a 400mio EUR turnover), Board Member for more than 8 years at Regina Maria (60mio EUR turnover) and Board Member at Walmark (100mio EUR turnover) since February 2016. In the past 14 years he has been working mostly with top-level investment funds implicated in mergers & acquisitions in the healthcare industry, being directly involved in 80 due diligence processes, of which 15 finalized transactions across CEE countries, Ukraine and Turkey (including one award-winning transaction - the acquisition of Terapia SA by Ranbaxy for $ 324m and the acquisition of Regina Maria by MEP for more than EUR 100m). In 2013 he sold his 49% of the shares held in Labormed (60mio EUR turnover) to Alvogen. In Romania he participated as project leader in the creation of the first major private hospitals and the country's first stem cell bank.